Kairos Pharma, Ltd.
KAPA
$0.8133
$0.02833.61%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.74% | 45.28% | -9.66% | 1.67% | 719.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.78% | 33.45% | 4.72% | 127.78% | 505.00% |
| Operating Income | -32.78% | -33.45% | -4.72% | -127.78% | -505.00% |
| Income Before Tax | 12.34% | -235.58% | -7.20% | -121.23% | -470.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.34% | -235.58% | -7.20% | -121.23% | -470.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.34% | -235.58% | -7.20% | -121.23% | -470.41% |
| EBIT | -32.78% | -33.45% | -4.72% | -127.78% | -505.00% |
| EBITDA | -34.03% | -38.87% | -5.81% | -187.21% | -649.29% |
| EPS Basic | 31.07% | -217.88% | -5.26% | -117.02% | -458.95% |
| Normalized Basic EPS | -10.99% | -217.46% | -4.90% | -117.05% | -457.98% |
| EPS Diluted | 31.07% | -217.88% | -5.26% | -117.02% | -458.95% |
| Normalized Diluted EPS | -10.99% | -217.46% | -4.90% | -117.05% | -457.98% |
| Average Basic Shares Outstanding | 27.16% | 5.57% | 2.21% | 2.21% | 1.85% |
| Average Diluted Shares Outstanding | 27.16% | 5.57% | 2.21% | 2.21% | 1.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |